{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:38:34Z","timestamp":1790807914726,"version":"4.1.0"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T00:00:00Z","timestamp":1522800000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002997","name":"Nierstichting","doi-asserted-by":"publisher","award":["13OCA27, 13OI116, KFB 11.007, IP 10.22, 16OKK01"],"award-info":[{"award-number":["13OCA27, 13OI116, KFB 11.007, IP 10.22, 16OKK01"]}],"id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2015\/18\/M\/NZ6\/00334, 2014\/14\/E\/NZ6\/00182"],"award-info":[{"award-number":["2015\/18\/M\/NZ6\/00334, 2014\/14\/E\/NZ6\/00182"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.00612","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T04:53:45Z","timestamp":1522817625000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases"],"prefix":"10.3389","volume":"9","author":[{"given":"Marloes A. H. M.","family":"Michels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole C. A. J.","family":"van de Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Okr\u00f3j","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Blom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne A. W.","family":"van Kraaij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena B.","family":"Volokhina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambertus P. W. J.","family":"van den Heuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,4,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1056\/nejm200104053441406","article-title":"Complement. First of two parts","volume":"344","author":"Walport","year":"2001","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.imbio.2015.04.006","article-title":"The membrane attack complex as an inflammatory trigger","volume":"221","author":"Morgan","year":"2016","journal-title":"Immunobiology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system part I\u2014molecular mechanisms of activation and regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1111\/j.1582-4934.2008.00350.x","article-title":"The alternative complement pathway revisited","volume":"12","author":"Harboe","year":"2008","journal-title":"J Cell Mol Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00281-017-0661-x","article-title":"The properdin pathway: an \u201calternative activation pathway\u201d or a \u201ccritical amplification loop\u201d for C3 and C5 activation?","volume":"40","author":"Harrison","year":"2018","journal-title":"Semin Immunopathol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/joim.12338","article-title":"Complement regulators in human disease: lessons from modern genetics","volume":"277","author":"Liszewski","year":"2015","journal-title":"J Intern Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nri2620","article-title":"Complement regulators and inhibitory proteins","volume":"9","author":"Zipfel","year":"2009","journal-title":"Nat rev Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3831","DOI":"10.4049\/jimmunol.1203487","article-title":"Complement in immune and inflammatory disorders: pathophysiological mechanisms","volume":"190","author":"Ricklin","year":"2013","journal-title":"J immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.molimm.2005.06.015","article-title":"Complement and diseases: defective alternative pathway control results in kidney and eye diseases","volume":"43","author":"Zipfel","year":"2006","journal-title":"Mol Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/j.1600-065X.2008.00641.x","article-title":"The spectrum of complement alternative pathway-mediated diseases","volume":"223","author":"Holers","year":"2008","journal-title":"Immunol Rev"},{"key":"B12","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1053\/j.ajkd.2015.03.040","article-title":"Glomerular diseases dependent on complement activation, including atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, and C3 glomerulopathy: core curriculum 2015","volume":"66","author":"Noris","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2249.2007.03552.x","article-title":"Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H","volume":"151","author":"de Cordoba","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.molimm.2015.03.012","article-title":"The role of complement in C3 glomerulopathy","volume":"67","author":"Zipfel","year":"2015","journal-title":"Mol Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/ki.2012.63","article-title":"Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies","volume":"82","author":"Servais","year":"2012","journal-title":"Kidney Int"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/ki.2013.377","article-title":"C3 glomerulopathy: consensus report","volume":"84","author":"Pickering","year":"2013","journal-title":"Kidney Int"},{"key":"B17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00467-015-3310-4","article-title":"C3 glomerulopathy","volume":"32","author":"Riedl","year":"2017","journal-title":"Pediatr nephrol"},{"key":"B18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4049\/jimmunol.116.1.1","article-title":"C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase","volume":"116","author":"Daha","year":"1976","journal-title":"J immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2215\/cjn.07900811","article-title":"Causes of alternative pathway dysregulation in dense deposit disease","volume":"7","author":"Zhang","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1034\/j.1399-3038.2001.012003166.x","article-title":"Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: a long-term follow-up","volume":"12","author":"Schwertz","year":"2001","journal-title":"Pediatr Allergy Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/ki.2012.212","article-title":"C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up","volume":"82","author":"Sethi","year":"2012","journal-title":"Kidney Int"},{"key":"B22","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2215\/cjn.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"E1445","DOI":"10.1002\/humu.21256","article-title":"Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome","volume":"31","author":"Maga","year":"2010","journal-title":"Hum Mutat"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2215\/cjn.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/nrneph.2012.214","article-title":"Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies","volume":"8","author":"Zuber","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2017.11.019","article-title":"Patterns of clinical response to eculizumab in patients with C3 glomerulopathy","author":"Le Quintrec","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1055\/s-0034-1375299","article-title":"Treatment of C3 glomerulopathy with complement blockers","volume":"40","author":"Vivarelli","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.imbio.2016.06.008","article-title":"Complement analysis 2016: clinical indications, laboratory diagnostics and quality control","volume":"221","author":"Prohaszka","year":"2016","journal-title":"Immunobiology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/ki.2012.250","article-title":"Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation","volume":"82","author":"Paixao-Cavalcante","year":"2012","journal-title":"Kidney Int"},{"key":"B32","first-page":"240","article-title":"Biological significance of the C3 nephritic factor in membranoproliferative glomerulonephritis","volume":"18","author":"Schena","year":"1982","journal-title":"Clin Nephrol"},{"key":"B33","first-page":"163","article-title":"Characteristics of a benign subtype of dense deposit disease: comparison with the progressive form of this disease","volume":"20","author":"Klein","year":"1983","journal-title":"Clin Nephrol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00467-013-2605-6","article-title":"C3 nephritic factor associated with C3 glomerulopathy in children","volume":"29","author":"Nicolas","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1016\/S0022-3476(05)82711-8","article-title":"Evidence that production of autoantibody to the alternative pathway C3 convertase is a normal physiologic event","volume":"116","author":"Spitzer","year":"1990","journal-title":"J Pediatr"},{"key":"B36","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.clim.2016.06.001","article-title":"A healthy female with C3 hypocomplementemia and C3 nephritic factor","volume":"169","author":"Egan","year":"2016","journal-title":"Clin immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/cei.12388","article-title":"A novel method for direct measurement of complement convertases activity in human serum","volume":"178","author":"Blom","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.4049\/jimmunol.174.4.2084","article-title":"Complement inhibitor of C5 activation from the soft tick Ornithodoros moubata","volume":"174","author":"Nunn","year":"2005","journal-title":"J immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.2215\/cjn.01820214","article-title":"Defining the complement biomarker profile of C3 glomerulopathy","volume":"9","author":"Zhang","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1093\/ndt\/gfq010","article-title":"Genetic disorders in complement (regulating) genes in patients with atypical haemolytic uraemic syndrome (aHUS)","volume":"25","author":"Westra","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"B41","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1073\/pnas.0603420103","article-title":"Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome","volume":"104","author":"Goicoechea de Jorge","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B42","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/cei.12426","article-title":"Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission","volume":"181","author":"Volokhina","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1021\/acs.bioconjchem.6b00369","article-title":"PASylated coversin, a C5-specific complement inhibitor with extended pharmacokinetics, shows enhanced anti-hemolytic activity in vitro","volume":"27","author":"Kuhn","year":"2016","journal-title":"Bioconjug Chem"},{"key":"B44","first-page":"209","article-title":"Regulation of the C3 nephritic factor stabilized C3\/C5 convertase of complement by purified human erythrocyte C3b receptor","volume":"50","author":"Daha","year":"1982","journal-title":"Clin Exp Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1073\/pnas.73.9.3268","article-title":"Control of the amplification convertase of complement by the plasma protein beta1H","volume":"73","author":"Weiler","year":"1976","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B46","first-page":"449","article-title":"Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor","volume":"68","author":"Ito","year":"1989","journal-title":"Immunology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/j.1365-2249.1992.tb06984.x","article-title":"Significance of C3 nephritic factor (C3NeF) in non-hypocomplementaemic serum with membranoproliferative glomerulonephritis (MPGN)","volume":"89","author":"Ohi","year":"1992","journal-title":"Clin Exp Immunol"},{"key":"B48","first-page":"73","article-title":"Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro","volume":"65","author":"Mollnes","year":"1986","journal-title":"Clin Exp Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S0272-6386(12)81018-3","article-title":"Patterns of complement activation in idiopathic membranoproliferative glomerulonephritis, types I, II, and III","volume":"16","author":"Varade","year":"1990","journal-title":"Am J Kidney Dis"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.kint.2017.04.017","article-title":"C5 nephritic factors drive the biological phenotype of C3 glomerulopathies","volume":"92","author":"Marinozzi","year":"2017","journal-title":"Kidney Int"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.molimm.2010.02.002","article-title":"Anti-factor B autoantibody in dense deposit disease","volume":"47","author":"Strobel","year":"2010","journal-title":"Mol Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1681\/ASN.2016030343","article-title":"Anti-factor B and anti-C3b autoantibodies in C3 glomerulopathy and Ig-associated membranoproliferative GN","volume":"28","author":"Marinozzi","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1056\/NEJMc1107484","article-title":"Combined C3b and factor B autoantibodies and MPGN type II","volume":"365","author":"Chen","year":"2011","journal-title":"N Engl J Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2215\/cjn.03480708","article-title":"Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients","volume":"4","author":"Nasr","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.imbio.2012.07.021","article-title":"Complement dysregulation and disease: from genes and proteins to diagnostics and drugs","volume":"217","author":"de Cordoba","year":"2012","journal-title":"Immunobiology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1016\/j.molimm.2011.04.024","article-title":"Complement activation by (auto-) antibodies","volume":"48","author":"Daha","year":"2011","journal-title":"Mol Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"5129","DOI":"10.4049\/jimmunol.1402770","article-title":"Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases","volume":"194","author":"Blanc","year":"2015","journal-title":"J immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrneph.2016.99","article-title":"Anti-complement-factor H-associated glomerulopathies","volume":"12","author":"Durey","year":"2016","journal-title":"Nat Rev Nephrol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00612\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T22:39:16Z","timestamp":1693607956000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00612\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,4]]},"references-count":58,"alternative-id":["10.3389\/fimmu.2018.00612"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.00612","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,4]]},"article-number":"612"}}